Assessment of the Health and Lifestyle Tool
Study to Evaluate the Digital Health and Lifestyle Tool Developed at the University of Gothenburg
1 other identifier
interventional
300
1 country
1
Brief Summary
The overall aim of the study is to evaluate a digital lifestyle intervention that has been developed in an academic setting at the University of Gothenburg, Sweden. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. The effects of the tool on HbA1c, reflecting long-term blood glucose, will be evaluated in patients with type 2 diabetes. The study will contain two phases. The study consists of a three-month period in which participants are randomly assigned to usual care or access to the intervention tool, followed by an open-label three-year observation period during which participants have access to the tool in addition to ordinary healthcare and are compared with matched controls on usual care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable diabetes-mellitus-type-2
Started Jan 2021
Longer than P75 for not_applicable diabetes-mellitus-type-2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 30, 2020
CompletedFirst Posted
Study publicly available on registry
November 10, 2020
CompletedStudy Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
July 16, 2025
July 1, 2025
6 years
October 30, 2020
July 13, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Change of long-term blood glucose concentration measured as glycated hemoglobin at 3 months
Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at 3 months relative to baseline compared between participants with access to the tool and on usual care.
3 months
Change of long-term blood glucose concentration measured as glycated hemoglobin at one year
Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at one year relative to baseline between participants who use the tool as recommended and matched controls on usual care
One year of the open-label observation period
Secondary Outcomes (6)
Change of long-term blood glucose concentration measured as glycated hemoglobin at three years
Three years of the open-label observation period
Body weight
3 months, 1 year and 3 years
Insulin resistance
3 months, 1 year and 3 years
Fasting blood glucose concentration
3 months, 1 year and 3 years
Physical activity in calories per day
3 years
- +1 more secondary outcomes
Other Outcomes (1)
Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.
1 year and 3 years
Study Arms (2)
Access to tool
EXPERIMENTALAccess to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
Usual care
PLACEBO COMPARATORThey are followed by their ordinary healthcare provider.
Interventions
Eligibility Criteria
You may qualify if:
- Patients with type 2 diabetes at or above 35 years of age
- Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication or diagnosed according to the WHO criteria (random plasma glucose \>11.1 mmol/L or fasting glucose \>7.0 mmol/L or HbA1C ≥6.5%).
- written informed consent.
You may not qualify if:
- type 1 diabetes, MODY or secondary diabetes
- conditions or treatments that in the judgement of the Investigator could affect the study evaluation
- inability to understand written Swedish
- connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region Skanelead
Study Sites (1)
Clinical Research Center
Malmo, Skåne County, 20502, Sweden
Related Publications (2)
Salunkhe VA, Sinha N, Ahlqvist E, Prasad RB, Johansson S, Abrahamsson B, Rosengren AH. Digital lifestyle treatment improves long-term metabolic control in type 2 diabetes with different effects in pathophysiological and genetic subgroups. NPJ Digit Med. 2023 Oct 26;6(1):199. doi: 10.1038/s41746-023-00946-0.
PMID: 37884680DERIVEDDwibedi C, Abrahamsson B, Rosengren AH. Effect of Digital Lifestyle Management on Metabolic Control and Quality of Life in Patients with Well-Controlled Type 2 Diabetes. Diabetes Ther. 2022 Mar;13(3):423-439. doi: 10.1007/s13300-022-01214-2. Epub 2022 Feb 12.
PMID: 35150403DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anders Rosengren
Region Skåne
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 30, 2020
First Posted
November 10, 2020
Study Start
January 1, 2021
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
July 16, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Data will be available after publication.
- Access Criteria
- To researchers who provide a methodologically sound proposal in order to achieve the aims of that proposal. Proposals should be directed by email to internetverktyg@gu.se
Individual participant data that underlie the results will be shared after deidentification.